Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
Marco Cerrano, Massimiliano Bonifacio, Matteo Olivi, Antonio Curti, Michele Malagola, Michelina Dargenio, Anna Maria Scattolin, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Ilaria Tanasi, Patrizia Zappasodi, Roberta La Starza, Nicola Stefano Fracchiolla, Patrizia Chiusolo, Luisa Giaccone, Maria Ilaria Del Principe, Fabio Giglio, Marzia Defina, Claudio Favre, Carmelo Rizzari, Barbara Castella, Giovanni Pizzolo, Felicetto Ferrara, Sabina Chiaretti, Robin Foà
Abstract
: Not available.
Topics & Concepts
MedicineDaratumumabChemotherapyInternal medicineOncologyObservational studyRefractory (planetary science)Retrospective cohort studyMEDLINEYoung adultMitoxantroneLymphoblastic LeukemiaDexamethasoneIntensive care medicineAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research